Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04555525 · ClinicalTrials.gov registry record · Phase 4
A Pilot Study on the Use of Seysara for Rosacea
A Phase 4 study of Acne Rosacea, sponsored by Derm Research, P.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04555525: Completed Phase 4 study of Acne Rosacea, sponsored by Derm Research, P.
NCT04555525 is a Phase 4 study of Acne Rosacea that has completed, run by Derm Research, P. The registered enrollment target is 100 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04555525, a Phase 4 study of Acne Rosacea, has completed, sponsored by Derm Research, P.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study is comprised of 5 visits: screening, baseline, week 4, week 8, and week 12. Investigators will perform rosacea IGA (Investigator Global Assessment,) inflammatory lesion count, record adverse events and con meds, and ask each subject to complete a DLQI (Dermatology Life Quality Index.)
Primary Outcome
Percent of subjects achieving clear or almost clear on IGA. The Investigator will score rosacea at each visit as per the following IGA: 0 = Clear (No inflammatory lesions present, no erythema); 1 = Almost Clear (Very few small papules/pustules, very mild erythema present); 2 Mild (Few small or large papules/pustules, moderate erythema); 3= Moderate (Several small or large papules/pustules, moderate erythema); 4 = Severe (Numerous small and/or large papules/pustules, severe erythema)
Conditions Studied
Interventions
- DRUG sarecycline
- DIETARY_SUPPLEMENT Centrum Adult Multivitamin
Study Locations (1)
Kentucky
- Skin Sciences, PLLC - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2020-10-01 |
| Phase | Phase 4 |
What the finished NCT04555525 record still lists
NCT04555525 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Acne Rosacea appearing as the primary indexed condition, and to 2 interventions - of which sarecycline is the first listed.
NCT04555525 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT04555525 about?
NCT04555525 is a clinical study titled "A Pilot Study on the Use of Seysara for Rosacea". This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study is comprised of 5 visits: screen...
What is the current status of trial NCT04555525?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2019-04-15. Estimated completion is 2020-10-01.
What conditions does trial NCT04555525 study?
This clinical trial studies the following conditions: Acne Rosacea.
What interventions are being tested in trial NCT04555525?
The interventions under investigation include: sarecycline (DRUG), Centrum Adult Multivitamin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04555525?
This trial is sponsored by Derm Research, P, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04555525 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04555525's enrollment target sits among peer trials
100 770th of 2000 higher than 1,149 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI